Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

782.33 +11.54 (+1.50%)
Streaming Delayed Price Updated: 11:48 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
49 50 Next >
News headline image
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review ↗
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall ↗
Excluding the year-earlier impact of the Covid drug, third-quarter sales grew 11%. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals: Q3 Earnings Insights ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange... 
Via Benzinga
News headline image
Analyst Ratings for Regeneron Pharmaceuticals ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2022 ↗
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’ ↗
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
News headline image
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy? ↗
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These two durable companies can navigate the market downturn and beyond. 
Via The Motley Fool
News headline image
Steady As She Goes With Healthcare Stocks ↗
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports. 
Via Talk Markets
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $5,000 Today ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.25% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022 ↗
Upgrades 
Via Benzinga
News headline image
13 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
Over the past 3 months, 13 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Why Cash-Rich Companies And #ETFs Are Beating The Market? ↗
Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest... 
Via Talk Markets
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
News headline image
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product ↗
 
Via Benzinga
News headline image
Moderna, Eli Lilly And This Biotechnology Stock Insiders Are Selling ↗
The Nasdaq Composite tumbled by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
These 7 Biotech Stocks Are Set to Boom in 2023 ↗
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
News headline image
2 Top Healthcare Stocks to Buy Right Now ↗
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
News headline image
Eaton, Wynn Resorts, Lamar Advertising And This Pharma Company Are CNBC's Final Trades ↗
On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr. Wonderful," chose Lamar Advertising Co. (NASDAQ: LAMR). 
Via Benzinga
News headline image
Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307M ↗
The SPDR S&P 500 ETF Trust (NYSE: SPY) struggled in September, historically its worst month of the year. 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ↗
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
News headline image
13 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Whale Trades For October 03 ↗
Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
News headline image
What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.